An Open Label Phase II Study of Tipifarnib in Advanced Non-Hematological Malignancies With HRAS Mutations
Phase of Trial: Phase II
Latest Information Update: 16 Oct 2017
At a glance
- Drugs Tipifarnib (Primary)
- Indications Head and neck cancer; Solid tumours; Squamous cell cancer; Thyroid cancer
- Focus Proof of concept; Therapeutic Use
- Sponsors Kura Oncology
- 16 Oct 2017 According to a Kura Oncology media release, data will be presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2017.
- 11 Oct 2017 Planned End Date changed from 1 Dec 2017 to 1 Aug 2018.
- 11 Oct 2017 Planned primary completion date changed from 1 Sep 2017 to 1 Mar 2018.